Omalizumab and Long-term Quality of Life Outcomes in Patients with Moderate-to-severe Allergic Asthma: a Systematic Review

Overview

Journal Ther Adv Respir Dis

Publisher Sage Publications

Specialties Pharmacology
Pulmonary Medicine

Date 2019 May 1

PMID 31035904

Citations 6

Authors

Giorgio Lorenzo Colombo

Sergio Di Matteo

Chiara Martinotti

Martina Oselin

Maria Chiara Valentino

Giacomo Matteo Bruno

Claudia Pitotti

Francesco Menzella

Affiliations

Soon will be listed here.

Abstract

Background: Asthma is a highly prevalent chronic inflammatory airways disease, with a considerable impact on quality of life (QoL). To express the effects of asthma on patients' subjective experience, patient-reported outcomes (PROs) represent an important instrument. The asthma QoL questionnaire (AQLQ) is one of the main PROs among these.

Materials And Methods: To identify long-term asthma-related QoL outcomes associated with omalizumab therapy in patients with moderate-to-severe asthma, we developed a systematic review according to the PRISMA guidelines. Published real-world effectiveness studies of adults or adolescents (12 years or older) with moderate-to-severe allergic asthma treated with omalizumab for at least 48 weeks were reviewed. Sources used were Medline ( PubMed), the Cochrane Library and Google Scholar up to February 2018. In addition, a cross-referencing search was conducted to complete the revision.

Results: A total of 255 potential papers were identified in the first search through the database. After full-text viewing, eight articles were finally included in the review. We summarized the results according to the study design, patient baseline characteristics and effectiveness outcomes assessed by AQLQ score results: variation from baseline to the end of study. Results confirmed the long-term benefits of omalizumab as an add-on therapy in patients with uncontrolled moderate-to-severe allergic asthma. Since there is a lot of evidence on omalizumab effectiveness, we aimed to focus on how a therapy can change patient's QoL in a long time period. Data showed long-term effects of omalizumab treatment on subjective (PROs) and objective (lung function, corticosteroid use, hospitalizations, asthma exacerbation) effectiveness measures.

Conclusion: Studies included in our review were observational trials that, due to their design, present a potential risk of selection bias in the patients included. Beyond this limit, the evaluation of QoL using the AQLQ showed a clear increase over time, following both 48 weeks and 9 years of observation, where QoL improvements still were significant over baseline values.

Citing Articles

Current Biologic Therapies for Severe Asthma and Real-World Data: Are Expectations Being Met?.

Villamanan E, Laorden D, Granda P, Sobrino C, De Andres S, Carpio C J Clin Med. 2024; 13(23).

PMID: 39685611 PMC: 11642429. DOI: 10.3390/jcm13237152.

Effect of biologic therapies on quality of life in severe asthma: Findings from the PRISM study.

Rhyou H, Kim H, Song W, Lee S, Kim S, Kwon J World Allergy Organ J. 2024; 17(9):100957.

PMID: 39252792 PMC: 11382106. DOI: 10.1016/j.waojou.2024.100957.

[Consensus document for severe asthma in adults. 2022 update].

Alvarez-Gutierrez F, Blanco-Aparicio M, Casas-Maldonado F, Plaza V, Gonzalez-Barcala F, Carretero-Gracia J Open Respir Arch. 2023; 4(3):100192.

PMID: 37496585 PMC: 10369632. DOI: 10.1016/j.opresp.2022.100192.

Omalizumab for the treatment of patients with severe allergic asthma with immunoglobulin E levels above >1500 IU/mL.

Menzella F, Just J, Schwab Sauerbeck I, Mailaender C, Saccheri F, Thonnelier C World Allergy Organ J. 2023; 16(6):100787.

PMID: 37332525 PMC: 10276275. DOI: 10.1016/j.waojou.2023.100787.

Therapeutic Modalities for Asthma, COPD, and Pathogenesis of COVID-19: Insights from the Special Issue.

Sohal S J Clin Med. 2022; 11(15).

PMID: 35956140 PMC: 9369734. DOI: 10.3390/jcm11154525.

References

Juniper E, OByrne P, Guyatt G, Ferrie P, King D . Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999; 14(4):902-7. DOI: 10.1034/j.1399-3003.1999.14d29.x. View

Neslusan C, Crown W, Torres A . Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related hospitalizations and emergency department visits. J Allergy Clin Immunol. 2002; 109(1):57-62. DOI: 10.1067/mai.2002.120554. View

Fuhlbrigge A, Adams R, Guilbert T, Grant E, Lozano P, Janson S . The burden of asthma in the United States: level and distribution are dependent on interpretation of the national asthma education and prevention program guidelines. Am J Respir Crit Care Med. 2002; 166(8):1044-9. DOI: 10.1164/rccm.2107057. View

Cisternas M, Blanc P, Yen I, Katz P, Earnest G, Eisner M . A comprehensive study of the direct and indirect costs of adult asthma. J Allergy Clin Immunol. 2003; 111(6):1212-8. DOI: 10.1067/mai.2003.1449. View

. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J. 2003; 22(3):470-7. DOI: 10.1183/09031936.03.00261903. View

Bateman E, Boushey H, Bousquet J, Busse W, Clark T, Pauwels R . Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004; 170(8):836-44. DOI: 10.1164/rccm.200401-033OC. View

Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J . Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005; 60(3):309-16. DOI: 10.1111/j.1398-9995.2004.00772.x. View

Niebauer K, Dewilde S, Fox-Rushby J, Revicki D . Impact of omalizumab on quality-of-life outcomes in patients with moderate-to-severe allergic asthma. Ann Allergy Asthma Immunol. 2006; 96(2):316-26. DOI: 10.1016/S1081-1206(10)61242-2. View

Walker S, Monteil M, Phelan K, Lasserson T, Walters E . Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev. 2006; (2):CD003559. DOI: 10.1002/14651858.CD003559.pub3. View

10.

Partridge M, van der Molen T, Myrseth S, Busse W . Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med. 2006; 6:13. PMC: 1483837. DOI: 10.1186/1471-2466-6-13. View

11.

Haselkorn T, Borish L, Miller D, Weiss S, Wong D . High prevalence of skin test positivity in severe or difficult-to-treat asthma. J Asthma. 2006; 43(10):745-52. DOI: 10.1080/02770900601031540. View

12.

Cazzoletti L, Marcon A, Janson C, Corsico A, Jarvis D, Pin I . Asthma control in Europe: a real-world evaluation based on an international population-based study. J Allergy Clin Immunol. 2007; 120(6):1360-7. DOI: 10.1016/j.jaci.2007.09.019. View

13.

Bahadori K, Doyle-Waters M, Marra C, Lynd L, Alasaly K, Swiston J . Economic burden of asthma: a systematic review. BMC Pulm Med. 2009; 9:24. PMC: 2698859. DOI: 10.1186/1471-2466-9-24. View

14.

Brusselle G, Michils A, Louis R, Dupont L, Van de Maele B, Delobbe A . "Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respir Med. 2009; 103(11):1633-42. DOI: 10.1016/j.rmed.2009.06.014. View

15.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

16.

Moore W, Meyers D, Wenzel S, Teague W, Li H, Li X . Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2009; 181(4):315-23. PMC: 2822971. DOI: 10.1164/rccm.200906-0896OC. View

17.

Hyland M, Finnis S, Irvine S . A scale for assessing quality of life in adult asthma sufferers. J Psychosom Res. 1991; 35(1):99-110. DOI: 10.1016/0022-3999(91)90011-c. View

18.

Rodrigo G, Neffen H, Castro-Rodriguez J . Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest. 2010; 139(1):28-35. DOI: 10.1378/chest.10-1194. View

19.

Pace E, Ferraro M, Bruno A, Chiappara G, Bousquet J, Gjomarkaj M . Clinical benefits of 7 years of treatment with omalizumab in severe uncontrolled asthmatics. J Asthma. 2011; 48(4):387-92. DOI: 10.3109/02770903.2011.561512. View

20.

Dal Negro R, Pradelli L, Tognella S, Micheletto C, Iannazzo S . Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy. Eur Ann Allergy Clin Immunol. 2011; 43(2):45-53. View